Internal Reference Number: FOI_6786
Date Request Received: 20/09/2022 00:00:00
Date Request Replied To: 05/10/2022 00:00:00
This response was sent via: By Email
Request Summary: Biologic medicines in Dermatology
Request Category: Researcher
| Question Number 1: How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: • Abatacept • Adalimumab - Humira • Adalimumab Biosimilar • Apremilast • Bimekizumab • Brodalumab • Certolizumab • Dimethyl fumarate • Etanercept - Enbrel • Etanercept Biosimilar • Golimumab • Guselkumab • Infliximab - Remicade • Infliximab Biosimilar • Ixekizumab • Risankizumab • Secukinumab • Tildrakizumab • Tofacitinib • Ustekinumab • Upadacitinib | |
| Answer To Question 1: Abatacept 0 Adalimumab Humira 6 Adalimumab biosimilar 19 Apremilast 8 BImekizumab 0 Brodalumab 10 Certolizumab <5 Dimethyl Fumarate 0 Etanercept Enbrel 0 Etanercetp biosimilar 0 Golimumab 0 Guselkumab 13 Infliximab Remicade 0 Infliximab biosimilar 0 Ixekizumab <5 Risankizumab 0 Secukinumab 6 Tildrakizumab 5 Tofacitinib <5 Ustekinumab 17 Upadacitinib 0 | |
| Question Number 2: How many patients were treated in the last 3 months by the Dermatology department for Psoriatic Arthritis (PsA) ONLY with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Apremilast • Certolizumab • Dimethyl fumarate • Etanercept - Enbrel • Etanercept Biosimilar • Guselkumab • Infliximab - Remicade • Infliximab Biosimilar • Ixekizumab • Risankizumab • Secukinumab • Ustekinumab | |
| Answer To Question 2: The Dermatology dept at SFT does not treat Psoriatic Arthritis (PsA). | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
